TaVNS for Acute Intracerebral Hemorrhage
Key facts
- Who runs it
- Beijing Tiantan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 186 people, planned
- Started
- 15 Sept 2025
- Expected to end
- Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- transcutaneous auricular vagus nerve stimulation device
- Sham device
- Record updated
- 15 January 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Patients with spontaneous supratentorial intracerebral hemorrhage
- Age between 18 and 80 years
- Onset within 72 hours
- Hematoma volume between 5 and 40 mL
- Glasgow Coma Scale (GCS) score greater than 8
- Written informed consent obtained from the patient or their legal representative
Who cannot take part
- Planned surgical treatment within 24 hours
- Use of medications that interfere with autonomic function (e.g., beta-blockers, theophylline, tricyclic antidepressants, or steroids) within 7 days before screening
- Secondary intracerebral hemorrhage (e.g., traumatic, tumor-related, vascular malformation, aneurysm, or coagulopathy-related)
- Primary intraventricular hemorrhage
- Parenchymal hemorrhage that ruptures into the ventricles, with blood completely filling one lateral ventricle, the third ventricle, the fourth ventricle or more than half of both lateral ventricles
- Progressive neurological or other severe diseases
- Pre-existing disability caused by previous illnesses: Modified Rankin Scale (mRS) score ≥ 3
- Patients with severe cardiomyopathy, heart failure, pacemaker implantation, atrial fibrillation, frequent premature beats, second-degree or higher atrioventricular block, or other severe arrhythmias
- Severe pulmonary disease, liver disease, renal insufficiency (glomerular filtration rate < 30 mL/min), active gastrointestinal bleeding, or malignant tumors with an expected survival of less than 3 months
- Patients with hyperthyroidism, hypothyroidism, syncope, epilepsy, multiple sclerosis, Parkinson's disease, multiple system atrophy, or other known disorders affecting autonomic nervous function
- Patients who cannot tolerate taVNS
- Congenital or acquired ear abnormalities preventing taVNS treatment
- Inability to comply with 10 days of treatment
- Pregnancy or within 30 days of delivery
- Participation in another interventional clinical trial
- Inability to obtain written informed consent from the participant or their legal representative
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Intracerebral hemorrhage
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with acute intracerebral hemorrhage (ICH). The taVNS intervention will be delivered using the BS-TVNS800-1 transcutaneous electrical stimulation therapy device (KERFUN, Shanxi, China). A total of 186 patients will be randomly assigned in a 1:1 ratio to either the taVNS group or the sham-taVNS group. The primary outcome is the relative volume of perihematoma edema assessed on day 10-14 after randomization. Adverse events associated with taVNS therapy will be systematically evaluated to assess its safety profile.
The 2 groups in the trial
- taVNS interventionExisting treatment, for comparison
Patients will receive taVNS therapy twice daily for 10 consecutive days, in addition to receiving guideline-adherent conventional treatment during hospitalization.
Treatment: transcutaneous auricular vagus nerve stimulation device
- Sham taVNS interventionSham treatment, for comparison
Patients will receive sham taVNS twice daily for 10 consecutive days, in addition to receiving guideline-adherent conventional treatment during their hospital stay.
Treatment: Sham device
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Acute Intracerebral Hemorrhage
- Criteria questions
- Built from NCT06918964, who can take part
- Record updated
- 15 January 2026